SCHEMBL7359011

SCHEMBL7359011

C=CC(c1ccccc1)n1ccnc1O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.37
▸ BRD4 O60885 1/20 0.33
▸ GAA P10253 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ TSHR P16473 1/20 0.31
▸ CYP19A1 P11511 3/20 0.31
▸ OPRK1 P41145 2/20 0.31
▸ CYP2D6 P10635 2/20 0.31
▸ OPRD1 P41143 2/20 0.31
▸ OPRM1 P35372 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ SLC6A2 P23975 1/20 0.30
▸ SLC6A4 P31645 1/20 0.30
▸ SLC6A3 Q01959 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10399939 0.81 CYP17A1 (0.42) CYP17A1KDM4EBRD4GAASMN1; SMN2
SCHEMBL9107464 0.76 CYP17A1 (0.39) CYP17A1KDM4EBRD4SMN1; SMN2POLB
SCHEMBL27762347 0.75 ALDH1A1 (0.47) CYP17A1KDM4EBRD4OPRK1CYP2D6
SCHEMBL28780266 0.75 ALDH1A1 (0.47) CYP17A1KDM4EBRD4OPRK1CYP2D6
SCHEMBL7453360 0.74 LMNA (0.38) GAATSHRCYP19A1OPRK1CYP2D6
SCHEMBL5139870 0.68 CYP17A1 (0.45) CYP17A1KDM4EBRD4TSHRCYP19A1
SCHEMBL8912868 0.68 HSD17B10 (0.59) CYP17A1POLBTSHRCYP2D6ALDH1A1
SCHEMBL29078122 0.67 CYP17A1 (0.51) CYP17A1KDM4ESMN1; SMN2TSHRCYP19A1
SCHEMBL27850181 0.67 CYP17A1 (0.51) CYP17A1KDM4ESMN1; SMN2TSHRCYP19A1
SCHEMBL1267769 0.67 CYP17A1 (0.82) CYP17A1CYP19A1OPRK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403805-B1 SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED JANSSEN PHARMACEUTICA N.V. (BE) 2002-06-11 — — US disclosed
US-20020068830-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES FREYNE EDDY JEAN EDGARD (BE) 2002-06-06 — — US disclosed
EP-0819122-B1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY JANSSEN PHARMACEUTICA NV (BE) 2002-03-06 — — EP disclosed
US-5994376-A PHOSPHODIESTERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 1999-11-30 — — US disclosed
EP-0819122-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY JANSSEN PHARMACEUTICA N.V. (BE) 1998-01-21 — — EP disclosed
WO-1996031485-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY JANSSEN PHARMACEUTICA N.V. (BE) 1996-10-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068830-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HRH2, CBR1, HRH1 CYP17A1 396/4885KDM4E 2378/4885BRD4 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback